135 related articles for article (PubMed ID: 37224792)
1. Multiplex serum immune profiling reveals circulating LAG-3 is associated with improved patient survival in high grade serous ovarian cancer.
Eurich K; De La Cruz P; Laguna A; Woodman M; McAdams J; Lips E; Ebott J; DiSilvestro J; Ribeiro J; James N
Gynecol Oncol; 2023 Jul; 174():200-207. PubMed ID: 37224792
[TBL] [Abstract][Full Text] [Related]
2. A Comprehensive Analysis of Prognostic Indicators in Serous Ovarian Cancer Based on Leukocyte Migration and Immune Microenvironment.
Pan J; Chen X; Yang L; Song Y; Liu J; Li L; Lin Y; Tang L; Qiu S; Xu Q
Front Biosci (Landmark Ed); 2023 Jun; 28(6):130. PubMed ID: 37395023
[TBL] [Abstract][Full Text] [Related]
3. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669
[TBL] [Abstract][Full Text] [Related]
4. Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
Fanale D; Brando C; Corsini LR; Cutaia S; Di Donna MC; Randazzo U; Filorizzo C; Lisanti C; Magrin L; Gurrera V; Romano R; Dimino A; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Giordano A; Chiantera V; Russo A; Bazan V; Iovanna JL
BMC Cancer; 2023 May; 23(1):437. PubMed ID: 37179293
[TBL] [Abstract][Full Text] [Related]
5. Targeting DUSP Activity as a Treatment for High-Grade Serous Ovarian Carcinoma.
Sanders BE; Yamamoto TM; McMellen A; Woodruff ER; Berning A; Post MD; Bitler BG
Mol Cancer Ther; 2022 Aug; 21(8):1285-1295. PubMed ID: 35587258
[TBL] [Abstract][Full Text] [Related]
6. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
[TBL] [Abstract][Full Text] [Related]
7. Tertiary Lymphoid Structures Are Associated with a Favorable Prognosis in High-Grade Serous Ovarian Cancer Patients.
Zhang K; Xie X; Zou LH; Guo SQ
Reprod Sci; 2023 Aug; 30(8):2468-2480. PubMed ID: 36759495
[TBL] [Abstract][Full Text] [Related]
8. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
[TBL] [Abstract][Full Text] [Related]
9. A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer.
Lo Riso P; Villa CE; Gasparoni G; Vingiani A; Luongo R; Manfredi A; Jungmann A; Bertolotti A; Borgo F; Garbi A; Lupia M; Laise P; Das V; Pruneri G; Viale G; Colombo N; Manzo T; Nezi L; Cavallaro U; Cacchiarelli D; Walter J; Testa G
Genome Med; 2020 Oct; 12(1):94. PubMed ID: 33121525
[TBL] [Abstract][Full Text] [Related]
10. Integrated weighted gene co-expression network analysis reveals biomarkers associated with prognosis of high-grade serous ovarian cancer.
Wang B; Chao S; Guo B
J Clin Lab Anal; 2022 Feb; 36(2):e24165. PubMed ID: 34997982
[TBL] [Abstract][Full Text] [Related]
11. Immune Modeling Analysis Reveals Immunologic Signatures Associated With Improved Outcomes in High Grade Serous Ovarian Cancer.
James NE; Miller K; LaFranzo N; Lips E; Woodman M; Ou J; Ribeiro JR
Front Oncol; 2021; 11():622182. PubMed ID: 33747935
[TBL] [Abstract][Full Text] [Related]
12. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
13. BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma.
Sallum LF; Andrade L; Bastos Eloy da Costa L; Ramalho S; Ferracini AC; Natal RA; Brito ABC; Sarian LO; Derchain S
Int J Gynecol Cancer; 2018 Mar; 28(3):437-447. PubMed ID: 29465506
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancer.
Gong W; Liu Y; Diamandis EP; Kiechle M; Bronger H; Dorn J; Dreyer T; Magdolen V
J Ovarian Res; 2020 Oct; 13(1):125. PubMed ID: 33087135
[TBL] [Abstract][Full Text] [Related]
15. A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.
Jin C; Xue Y; Li Y; Bu H; Yu H; Zhang T; Zhang Z; Yan S; Lu N; Kong B
Int J Gynecol Cancer; 2018 Jan; 28(1):51-58. PubMed ID: 28976449
[TBL] [Abstract][Full Text] [Related]
16. High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
Li M; Cheng X; Rong R; Gao Y; Tang X; Chen Y
BMC Cancer; 2020 Oct; 20(1):1032. PubMed ID: 33109151
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral expression analysis reveals that OX40 and TIM-3 are prominently expressed and have variable associations with clinical outcomes in high grade serous ovarian cancer.
James NE; Valenzuela AD; Emerson JB; Woodman M; Miller K; Hovanesian V; Ou J; Ribeiro JR
Oncol Lett; 2022 Jun; 23(6):188. PubMed ID: 35527785
[TBL] [Abstract][Full Text] [Related]
18. Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer.
Shah JS; Gard GB; Yang J; Maidens J; Valmadre S; Soon PS; Marsh DJ
Gynecol Oncol; 2018 Jan; 148(1):181-188. PubMed ID: 29132874
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer.
Hoffmann I; Dragomir MP; Monjé N; Keunecke C; Kunze CA; Schallenberg S; Marchenko S; Schmitt WD; Kulbe H; Sehouli J; Braicu IE; Jank P; Denkert C; Darb-Esfahani S; Horst D; Sinn BV; Sers C; Bischoff P; Taube ET
Neoplasia; 2023 Oct; 44():100934. PubMed ID: 37703626
[TBL] [Abstract][Full Text] [Related]
20. High
Li XF; Zhang HB; Huo Y
J Int Med Res; 2022 Nov; 50(11):3000605221135864. PubMed ID: 36366735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
